Literature DB >> 20008092

Treatment of a patient with remitting seronegative, symmetrical synovitis with pitting oedema with a humanized anti-interleukin-6 receptor antibody, tocilizumab.

Toshio Tanaka, Keisuke Hagihara, Yoshihito Shima, Masashi Narazaki, Atsushi Ogata, Ichiro Kawase, Tadamitsu Kishimoto.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 20008092     DOI： 10.1093/rheumatology/kep412

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN： 1462-0324            Impact factor:   7.580


× No keyword cloud information.
  4 in total

Review 1.  [Interleukin-6 inhibition as a potential therapeutic target in rheumatic diseases].

Authors:  C Iking-Konert; P Bartz-Bazzanella; D Falagan; M W Hofman; A Schwarting; T Dörner
Journal:  Z Rheumatol       Date:  2014-04       Impact factor: 1.372

2.  Remitting seronegative symmetric synovitis with pitting edema (RS3PE) with painful erythematous nodules.

Authors:  Nicholas Kevin Laidler; Thomas Delaney
Journal:  BMJ Case Rep       Date:  2020-04-22

3.  Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions.

Authors:  Atsushi Ogata; Toshio Tanaka
Journal:  Int J Rheumatol       Date:  2012-01-18

Review 4.  Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases.

Authors:  Toshio Tanaka; Tadamitsu Kishimoto
Journal:  Int J Biol Sci       Date:  2012-10-24       Impact factor: 6.580
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.